SightGlass Vision recently reported that eyeglasses the company designed to slow the progression of myopia in children have been successful so far, as indicated by axial length and cycloplegic spherical equivalent refraction change over 12 months.1
The company’s Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study (CYPRESS) is in the process of evaluating 256 children aged six to 10 years old who have between -0.75D and -4.50D of myopia. Participants were assigned either control lenses or one of two test lenses.1
One year into the three-year clinical trial, the company has announced that results “showed superiority of both test arms compared with control lenses.”1
“These findings are highly encouraging,” the company’s chief medical offer shared in a company release. “We look forward to additional data from the ongoing trial and sharing more information about these 12-month data in the near future.”1
Although promising, the results are based on a tightly controlled trial with several exclusion criteria that may limit the implications in clinical practice. Patients with previous or current contact lens wear, bifocals, progressive addition spectacles lenses or any form of myopia control treatment were excluded from the trial. Patients with astigmatism worse than -1.25D in either eye were also not eligible.2
1. PR Newswire. SightGlass Vision reports positive interim data from pivotal clinical trial of novel eyeglasses for myopia management in children. www.prnewswire.com/news-releases/sightglass-vision-reports-positive-interim-data-from-pivotal-clinical-trial-of-novel-eyeglasses-for-myopia-management-in-children-301032946.html. April 2, 2020. Accessed April 15, 2020.
2. Control of Myopia Using Novel Spectacle Lens Designs (CYPRESS). www.clinicaltrials.gov/ct2/show/NCT03623074?term=CYPRESS&draw=2&rank=2. Accessed April 15, 2020.